Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer

This is an open-label study of NMS-03305293 with Temozolomide (TMZ) in patients with Small Cell Lung Cancer (SCLC). The aim of this study is to determine the safety and tolerability, as well as to evaluate the anti-tumor efficacy and pharmacokinetics of NMS-03305293 in combination with TMZ.

Trial Details

NCT ID
NCT06931626
Phase
PHASE1
Sponsor
Nerviano Medical Sciences
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • NMS-03305293
  • Temozolomide
Locations (sample)
  • Peoria, Illinois, United States|40.69365,-89.58899
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Nashville, Tennessee, United States|36.16589,-86.78444

Key Eligibility Criteria

  • Histologically confirmed extensive-stage Small Cell Lung Cancer (SCLC); must have failed prior front-line platinum-based therapy including immune t…
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
  • Patient must have progressed radiographically on or after their most recent line of anticancer therapy and have measurable disease as defined by RE…
  • The interval from prior antitumor treatment should be at least 2 weeks or 5 half-lives, whichever longer for small-molecule agents and chemotherapi…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →